Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 387, Issue 10, 2014, Pages 909-919

  Kondo, Mitsuhiro ^a   Tahara, Atsuo ^a   Hayashi, Kazumi ^a   Abe, Masaki ^a   Inami, Hiroshi ^a   Ishikawa, Takeshi ^a   Ito, Hiroyuki ^a   Tomura, Yuichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

AS2444697; Chronic kidney disease; Inflammation; Interleukin 1 receptor associated kinase 4

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; PROTEIN KINASE INHIBITOR;

ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; INNERVATION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; METABOLISM; MOUSE; NEPHRECTOMY; PATHOLOGY; RAT; URINE; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MICE; MICE, INBRED BALB C; NEPHRECTOMY; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR;

EID: 84930920031     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-014-1023-z     Document Type: Article

References (28)

1. Carrero JJ, Stenvinkel P (2009) Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 4:S49-55
2. Cho ME, Kopp JB (2010) Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs 19:275-283
3. Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, Chaves P, Furberg C, Kuler L, Newman A (2004) Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 15:3184-3191
4. Ghosh SS, Krieg R, Massey HD, Sica DA, Fakhry I, Ghosh S, Gehr TW (2012) Curcumin and enalapril ameliorate renal failure by antagonizing inflammation in 5/6 nephrectomized rats: role of phospholipase and cyclooxygenase. Am J Physiol Renal Physiol 15:F439-454
5. Imanishi J, Ishikawa T, Imamura E, Mizuhara H, Iwaoka H, Evelyn B, Inami H, Mizutani T, Watanabe J, Usuda H, Nagashima S, Ito T, Kontani T, Shimizu Y, Mutoh S (2011) Anti-inflammatory profile of AS2444697, a novel interleukin-1 receptor-associated kinase-4 inhibitor. Arthritis Rheum 63:S390
6. Inami H, Mizutani T, Watanabe J, Usuda H, Nagashima S, Ito T, Aoyama N, Kontani T, Hayashida H, Terasawa T, Moritomo A, Ishikawa T, Hayashi K, Takeuchi M, Ohta M (2011) Oxazolecarboxamide derivatives as novel IRAK-4 inhibitors. 242nd ACS National Meeting & Exposision, MEDI 329.
7. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S (1995) Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47:1285-1294
8. Kim TW, Staschke K, Bulek K, Yao J, Peters K, Oh KH, Vandenburg Y, Xiao H, Qian W, Hamilton T, Min B, Sen G, Gilmour R, Li X (2007) A critical role for IRAK-4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med 14:1025-1036
9. Kim HJ, Vaziri ND, Norris K, An WS, Quiroz Y, Rodriguez-Iturbe B (2010) High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease. Clin Exp Nephrol 14:536-547
10. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J (1996) Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49:666-678
11. Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, Chrabieh M, Issekutz AC, Cunningham CK, Gallin J, Holland SM, Roifman C, Ehl S, Smart J, Tang M, Barrat FJ, Levy O, McDonald D, Day-Good NK, Miller R, Takada H, Hara T, Al-Hajjar S, Al-Ghonaium A, Speert D, Sanlaville D, Li X, Geissmann F, Vivier E, Marodi L, Garty BZ, Chapel H, Rodriguez-Gallego C, Bossuyt X, Abel L, Puel A, Casanova JL (2007) Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 204:2407-2422
12. Lambers Heerspink HJ, de Zeeuw D (2013) Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 76:536-550
13. Lebleu VS, Sugimoto H, Miller CA, Gattone VH 2nd, Kalluri R (2008) Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab Invest 88:284-292
14. Li S, Strelow A, Fontana EJ, Wesche H (2002) IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci U S A 16:5567-5572
15. Lin M, Tang SC (2013) Toll-like receptors: sensing and reacting to diabetic injury in the kidney. Nephrol Dial Transplant 0:1-11
16. Lin SL, Chiang WC, Chen YM, Lai CF, Tsai TJ, Hsieh BS (2005) The renoprotective potential of pentoxifylline in chronic kidney disease. J Chin Med Assoc 68:99-105
17. Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Pena AB, Lopez-Hernandez FJ (2010) Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther 128:61-81
18. Medvedev AE, Lentschat A, Kuhns DB, Blanco JC, Salkowski C, Zhang S, Arditi M, Gallin JI, Vogel SN (2003) Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 18:521-531
19. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65:1009-1016
20. Ortega LM, Fornoni A (2010) Role of cytokines in the pathogenesis of acute and chronic kidney disease, glomerulonephritis, and end-stage kidney disease. Int J Interf Cytokine Mediat Res 2:49-62
21. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA (1994) Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45:890-896
22. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jummah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A, Casanova JL (2003) Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 28:2076-2079
23. Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F (2013) IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. J Nephrol 26:86-93
24. Silverstein DM (2009) Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 24:1445-1452
25. Suliman ME, Stenvinkel P (2008) Contribution of inflammation to vascular disease in chronic kidney disease patients. Saudi J Kidney Dis Transpl 19:329-345
26. Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC (2002) Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 18:750-756
27. Uehara Y, Kawabata Y, Shirahase H, Wada K, Hashizume Y, Morishita S, Numabe A, Iwai J, Matsuoka H, Sugimoto T (1992) Radical scavenging properties of indapamide and renal protection in Dahl salt-sensitive rats. Hypertens Res 15:17-26
28. Wang Z, Wesche H, Stevens T, Walker N, Yeh WC (2009) IRAK-4 inhibitors for inflammation. Curr Top Med Chem 9:724-737